Abstract
Impulse Control Disorders (ICD) are psychiatric complications of Parkinson's Disease (PD), increasingly recognized, but which persist underdiagnosed and can be vert disruptive to the patient's family life, especially if they are not detected in time. Although one of its main risks is the use of dopamine agonists, these are not the only cause, they can be seen without realtion to medications ot any treatment for PD, therefore it should be questioned systematically by their presence and educate the patient and his family to be reported at any time. The objective of this chapter is to describe the different types of ICD, their risk factors and treatment.
References
Vargas A, Cardoso F. Impulse control and related disorders in Parkinson's disease. Arq Neuropsiquiatr. 2018;76(6):399-410.
Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson's disease. Int Rev Neurobiol. 2017;133:679-717.
Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disor. 2009;24:1561-70.
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-95.
Antonini A, Barone P, Bonuccelli U, Annoni K, Asgharnejad M, Stanzione P. ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2017;88:317-24.
Vela L, Martínez Castrillo JC, García Ruiz P, Gasca-Salas C, Macías Y, Pérez Fernández E, et al. The high prevalence of impulse control behaviors in patients with early-onset Parkinson's disease: A cross-sectional multicenter study. J Neurol Sci. 2016;368:150-4.
Antonini A, Siri C, Santangelo G, Cilia R, Poletti M, Canesi M, et al. Impulsivity and compulsivity in drugnaiive patients with Parkinson's disease. Mov Disord. 2011;26:464-8.
Sáez-Francàs N, Martí Andrés G, Ramírez N, Fàbreugues O, Alvarez-Sabin J, Casas M, et al. Clinical and psychopathological factors associated with impulse control disorders in Parkinson's disease. Neurología. 2016;31:231-8.
Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, et al. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85:840-4.
Auyeung M, Tsoi TH, Tang WK, Cheung CM, Lee CN, Li R, et al. Impulse control disorders in Chinese Parkinson's disease patients: the effect of ergot derived dopamine agonist. Parkinsonism Relat Disord. 2011;17:635-7.
de Chazeron I, Llorca PM, Chéreau-Boudet I, Blanc O, Perriot J, Ouchchane L et al. Hypersexuality and pathological gambling in Parkinson's disease: A cross-sectional case-control study. Mov Disord. 2011;26:2127-30.
Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord. 2012;18:155-60.
Ramírez Gómez CC, Serrano Dueñas M, Bernal O, Araoz N, Sáenz Farret M, Aldinio V, et al. A Multicenter comparative study of impulse control disorder in Latin American patients with Parkinson disease. Clin Neuropharmacol. 2017;40:51-55.
Isaias-Millan S, Pina-Fuentes D, Guzman-Astorga C, Cervantes-Arriaga A, Rodríguez-Violante M. Prevalencia de trastornos neuropsiquiátricos en pacientes con enfermedad de Parkinson (EP) no tratados. Gac Med Mex. 2016;152:357-63.
Rodríguez-Violante M, González-Latapi P, Cervantes-Arriaga A, Camacho-Ordoñez A, Weintraub D. Impulse control and related disorders in Mexican Parkinson's disease patients. Parkinsionism Relat Disord. 2014;20:907-10.
Voon V, Sohr M, Lang AE, Potenza MN, Siderowf AD, Whetteckey J, et al. Impulse control disorders in Parkinson disease: a multicenter case: control study. Ann Neurol. 2011;69:986-96.
Bernal-Pacheco O, Murcia DC. Impulsividad secundaria a agonistas dopa, una cifra más allá de la esperada. Poster VII Simposio Internacional de Movimientos Anormales. Cartagena, agosto 24-26 2017.
Siri C, Cilia R, Reali E, Pozzi B, Cereda E, Colombo A, et al. Longterm cognitive follow-up of Parkinson's disease patients with impulse control disorders. Mov Disord. 2015;30:696-704.
Morgante F, Fasano A, Ginevrino M, Petrucci S, Ricciardi L, Bove F, et al. Impulsive-compulsive behaviors in parkin-associated Parkinson disease. Neurology. 2016;87:1436-41.
Weintraub D, Sohr M, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol. 2010;68:963-8.
Thomas A, Bonanni L, Gambi F, Di Iorio A, Onofrj M. Pathological gambling in Parkinson disease is reduced by amantadine. Ann Neurol. 2010;68:400-4.
Okai D, Askey-Jones S, Samuel M, O'Sullivan SS, Chaudhuri KR, Martin A, et al. Trial of CBT for impulse control behaviors affecting Parkinson patients and their caregivers. Neurology. 2013;80:792-9.
Merola A, Romagnolo A, Rizzi L, Rizzone MG, Zibetti M, Lanotte M, et al. Impulse control behaviors and subthalamic deep brain stimulation in Parkinson disease. J Neurol. 2017;264:40-8.
Joutsa J, Martikainen K, Vahlberg T, Kaasinen V. Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism Relat Disord. 2012;18:1079-83.
Sohtaoglu M, Demiray DY, Kenangil G, Ozekmekçi S, Erginõz E. Long term follow-up of Parkinson's disease patients with impulse control disorders. Parkinsonism Relat Disord. 2010;16:334-7.
Spencer AH, Rickards H, Fasano A, Cavanna AE. The prevalence and clinical characteristics of punding in Parkinson's disease. Mov Disord. 2011;26:578-86.
Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F, et al. Dopamine dysregulation syndrome in Parkinson's disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014;85:311-8
Catalán MJ, Pablo-Fernández E, Villanueva C, Fernández-Diez S, Lapeña-Montero T, García-Ramos R, et al. Levodopa infusion improves impulsivity and dopamine dysregulation syndrome in Parkinson's disease. Mov Disord. 2013;28:2007-10.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.